tiprankstipranks
Trending News
More News >
Datametrex AI Limited (TSE:DM)
:DM

Datametrex AI (DM) AI Stock Analysis

Compare
87 Followers

Top Page

TSE:DM

Datametrex AI

(DM)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$0.10
▼(-2.00% Downside)
The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues and high leverage. Technical analysis also suggests a bearish trend. However, positive corporate events, including expansions and new purchase orders, provide some optimism for future growth.
Positive Factors
AI and Data Analytics Focus
The company's focus on AI and data analytics positions it well in a growing industry, leveraging advanced technologies to enhance decision-making and operational efficiency.
Diverse Revenue Streams
Diverse revenue streams from subscriptions, licensing, and consulting provide stability and flexibility, allowing the company to adapt to market demands and enhance earnings potential.
Strategic Partnerships
Strategic partnerships enhance service offerings and market reach, fostering growth opportunities and competitive advantages in the technology sector.
Negative Factors
Declining Revenue
Significant revenue decline indicates challenges in market demand or competitive positioning, impacting long-term financial stability and growth prospects.
High Leverage
High leverage suggests heavy reliance on debt financing, which can strain financial flexibility and increase risk during economic downturns.
Weak Cash Flow
Weak cash flow performance limits the company's ability to invest in growth opportunities and manage financial obligations, posing a risk to long-term sustainability.

Datametrex AI (DM) vs. iShares MSCI Canada ETF (EWC)

Datametrex AI Business Overview & Revenue Model

Company DescriptionDatametrex AI (DM) is a technology company specializing in artificial intelligence and data analytics solutions. The company operates primarily in the sectors of cybersecurity, health tech, and big data. Datametrex offers a range of core products and services, including advanced machine learning algorithms, predictive analytics tools, and AI-driven cybersecurity solutions designed to help organizations harness the power of their data for improved decision-making and operational efficiency.
How the Company Makes MoneyDatametrex AI generates revenue through multiple streams. The primary source of income is derived from the sale of its software solutions and services, which include subscription-based models for access to its AI platforms and analytics tools. Additionally, the company earns revenue through consulting services, where it provides expertise in data analytics and cybersecurity strategies to various clients. Partnerships with other technology firms and enterprises also play a significant role in its revenue model, as these collaborations can lead to joint product offerings and expanded market reach. Furthermore, Datametrex may benefit from government contracts and grants related to technology development in sectors such as health tech and cybersecurity, contributing to its overall earnings.

Datametrex AI Financial Statement Overview

Summary
Datametrex AI is facing significant financial challenges, with declining revenues, negative profitability, high leverage, and weak cash flow generation. The company needs to address these issues to improve financial stability and performance.
Income Statement
35
Negative
The company has experienced a significant decline in revenue over the past year, with a revenue growth rate of -43.31%. Profitability metrics are weak, with negative net profit and EBIT margins indicating ongoing losses. The gross profit margin is moderate at 47.35%, but overall financial performance is concerning due to persistent negative earnings.
Balance Sheet
40
Negative
The balance sheet shows high leverage with a debt-to-equity ratio of 2.80, indicating significant reliance on debt financing. Return on equity is negative, reflecting losses and poor shareholder returns. The equity ratio is low, suggesting limited financial stability. These factors highlight potential financial risks.
Cash Flow
30
Negative
Cash flow metrics are weak, with negative operating and free cash flows. The free cash flow growth rate is -27.04%, indicating deteriorating cash generation. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Overall, cash flow performance is concerning.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.82M6.49M7.80M30.49M49.03M12.38M
Gross Profit634.64K3.07M2.17M10.20M21.03M2.99M
EBITDA-1.42M-1.24M-6.95M-13.46M13.29M-3.60M
Net Income-2.98M-3.06M-19.14M-17.26M9.09M-5.01M
Balance Sheet
Total Assets8.48M4.99M12.71M36.00M42.64M10.00M
Cash, Cash Equivalents and Short-Term Investments312.44K427.11K1.13M9.41M17.99M1.97M
Total Debt4.79M1.84M5.19M4.53M253.77K518.58K
Total Liabilities8.05M4.33M11.70M13.23M10.15M6.75M
Stockholders Equity430.64K656.40K1.00M22.77M32.49M3.25M
Cash Flow
Free Cash Flow-756.28K-1.57M-6.94M-2.28M11.42M-611.50K
Operating Cash Flow-756.28K-1.22M-5.62M-249.09K11.45M-595.10K
Investing Cash Flow35.98K59.10K-969.15K-3.79M-234.41K-14.93K
Financing Cash Flow772.05K1.21M-254.18K-2.40M2.19M2.48M

Datametrex AI Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.09
Negative
100DMA
0.09
Negative
200DMA
Market Momentum
MACD
>-0.01
Positive
RSI
39.78
Neutral
STOCH
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DM, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DM.

Datametrex AI Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
46
Neutral
C$7.73M-0.79-58.58%-56.02%91.71%
41
Neutral
C$5.17M-4.35-3428.85%-15.33%47.13%
41
Neutral
C$3.13M-9.0913.01%20.00%
40
Underperform
C$8.31M-0.12-18.97%-55.19%
40
Underperform
C$4.19M-0.1722.81%11.13%
37
Underperform
C$5.97M-1.1233.92%-402.25%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:DM
Datametrex AI
0.09
-0.21
-70.00%
TSE:FARM
Deveron UAS
0.04
0.00
0.00%
TSE:VIS
Visionstate
0.02
0.00
0.00%
TSE:NERD
Nerds On Site
0.04
-0.03
-42.86%
TSE:PAID
XTM
0.02
-0.04
-66.67%
TSE:DCSI
Direct Communication Solutions
2.40
-4.80
-66.67%

Datametrex AI Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Datametrex Expands Walk-In Medical Services in Calgary and Edmonton
Positive
Dec 1, 2025

Datametrex AI Limited has announced the introduction of walk-in services at its Imagine Health Medical Clinics in Calgary and Edmonton, enhancing access to same-day medical care for urgent non-emergency needs. This expansion reflects the company’s commitment to improving healthcare accessibility and patient-focused care across Western Canada, with plans to further broaden its clinic network and service offerings.

Business Operations and Strategy
Datametrex AI Secures $650,000 in New Purchase Orders
Positive
Nov 27, 2025

Datametrex AI Limited has secured purchase orders worth approximately CAD $650,000 through its subsidiary, Datametrex Korea, marking a significant advancement in its expansion strategy. This achievement underscores the company’s role as a trusted IT infrastructure solutions provider and highlights its commitment to delivering exceptional value to global partners, reinforcing its presence in key international markets.

Business Operations and Strategy
Datametrex Expands Healthcare Services with New Physicians in Calgary and Edmonton
Positive
Nov 24, 2025

Datametrex AI Limited’s subsidiary, Imagine Health Medical Clinics, has expanded its team by adding four new physicians across its Calgary and Edmonton locations, enhancing its capacity to offer a broad spectrum of insured medical services. This strategic move aligns with the company’s objective to expand its healthcare division, ensuring high-quality, timely medical care for patients and supporting the growth of its healthcare services in these communities.

Business Operations and Strategy
Datametrex’s Imagine Health Opens New Edmonton South Clinic
Positive
Nov 21, 2025

Datametrex AI Limited’s subsidiary, Imagine Health Medical Clinics Ltd., has relocated its Edmonton South clinic to a modern facility, enhancing its ability to provide high-quality, patient-focused care. This move aligns with Imagine Health’s mission to meet the evolving healthcare needs of the community, offering a comprehensive range of services including family medicine and specialized medical care.

Business Operations and Strategy
Datametrex Expands Healthcare Reach with New Calgary Clinic
Positive
Nov 20, 2025

Datametrex AI Limited announced the relocation of its subsidiary, Imagine Health Medical Clinics, to a new location in Calgary’s Capitol Hill area. This move aims to enhance patient care and accessibility, reflecting the company’s commitment to providing high-quality healthcare services. The new facility is fully operational and accepting new patients, indicating a strategic expansion in the Calgary community.

Business Operations and Strategy
Datametrex Expands Healthcare Services with New Calgary Clinic
Positive
Nov 20, 2025

Datametrex AI Limited has announced the relocation of its subsidiary, Imagine Health Medical Clinics, to a new facility in Calgary’s Capitol Hill. This move aims to enhance patient care and accessibility, reflecting the company’s commitment to providing high-quality healthcare services. The new clinic is fully operational and accepting new patients, further solidifying Imagine Health’s presence in Calgary and its dedication to meeting the community’s healthcare needs.

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Datametrex AI Secures $5.1 Million Through Financing Closures
Positive
Nov 15, 2025

Datametrex AI Limited has successfully closed its non-brokered private placement and subscription receipt financing, raising a total of $5,133,500. The funds will be used to integrate the Yuzu Payment Solution into its technology division and support business expansion, including the establishment of a new clinic. The completion of the subscription receipt financing is crucial for the acquisition of Yuzu Payment Solution, with specific conditions set for the release of funds from escrow.

Private Placements and FinancingBusiness Operations and Strategy
Datametrex AI Sets Closing Date for $5.3 Million Financing
Positive
Nov 11, 2025

Datametrex AI Limited has announced the closing date for its non-brokered private placement and subscription receipt financing, set for November 14, 2025. The company aims to raise up to $5.3 million to support business expansion, the integration of Yuzu Payment Solution, and general working capital, potentially impacting its market positioning and operational capabilities.

Executive/Board ChangesRegulatory Filings and Compliance
Datametrex AI Appoints New Board Member to Strengthen Governance
Neutral
Oct 24, 2025

Datametrex AI Limited has appointed Mr. Enrico Moretti, a securities lawyer with extensive cross-border legal expertise, to its Board of Directors to fulfill the minimum director requirement under Exchange policies. This appointment aims to strengthen the company’s governance and compliance framework, as the company works diligently to address a trading halt imposed by the Exchange due to the previous deficiency in board composition. Mr. Moretti’s expertise is expected to be a valuable asset in enhancing the company’s corporate governance and regulatory compliance.

Private Placements and FinancingBusiness Operations and Strategy
Datametrex AI Upsizes Private Placement to Bolster Payment Solutions
Positive
Sep 29, 2025

Datametrex AI Limited has announced plans to upsize its non-brokered private placement financings, seeking approval from the TSX Venture Exchange to increase the private placement of common shares from $3 million to $4 million and the financing of subscription receipts from $1 million to $1.3 million. The proceeds will be used to integrate the Yuzu Payment Solution into Datametrex’s technology division, pursue merchant opportunities, and for general working capital. This strategic move aims to strengthen Datametrex’s position in the tech industry by enhancing its payment solutions and expanding its market reach.

Private Placements and FinancingBusiness Operations and Strategy
Datametrex AI Announces Financing for Yuzu Payment Integration
Positive
Sep 22, 2025

Datametrex AI Limited has announced the terms of its private placement financings, which include a non-brokered private placement of up to $3,000,000 of common shares and a non-brokered private placement of up to $1,000,000 of subscription receipts. The proceeds from these financings will be used to integrate the Yuzu Payment Solution into Datametrex’s technology division, aiming to generate revenue through merchant opportunities. This strategic move is expected to enhance Datametrex’s operations and strengthen its position in the fintech industry.

M&A TransactionsBusiness Operations and Strategy
Datametrex AI to Acquire Yuzu Payment Solution to Boost Growth in Payments Sector
Positive
Sep 15, 2025

Datametrex AI Limited has signed a non-binding Letter of Intent to acquire the Yuzu payment processing solution from Firstpayment Inc., a Montreal-based fintech company. This acquisition, valued at approximately $5.5 million, will be paid through the issuance of common shares and aims to commercialize Yuzu’s cryptocurrency payment solutions. The acquisition is expected to accelerate Datametrex’s growth in the payments sector and leverage existing relationships with various merchant categories, potentially generating new revenue streams. The transaction is subject to customary closing conditions and regulatory approvals.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 07, 2025